Publications by authors named "Jennifer Rene"
Article Synopsis
- A study was conducted to evaluate a fully automated insulin delivery system (using faster-acting insulin aspart and pramlintide) for people with type 1 diabetes that does not require meal input, compared to a system that requires precise carbohydrate counting.
- The trial involved 28 adults with type 1 diabetes, with 24 completing both intervention systems to determine which maintained glucose levels more effectively.
- Results indicated that the fully closed-loop system maintained glucose levels within the target range 74.3% of the time, while the hybrid system achieved 78.1%, showing that the new system was non-inferior despite slightly lower effectiveness.
Aim: To assess whether a FiASP-and-pramlintide closed-loop system has the potential to replace carbohydrate counting with a simple meal announcement (SMA) strategy (meal priming bolus without carbohydrate counting) without degrading glycaemic control compared with a FiASP closed-loop system.
Materials And Methods: We conducted a 24-hour feasibility study comparing a FiASP system with full carbohydrate counting (FCC) with a FiASP-and-pramlintide system with SMA. We conducted a subsequent 12-day outpatient pilot study comparing a FiASP-and-placebo system with FCC, a FiASP-and-pramlintide system with SMA, and a FiASP-and-placebo system with SMA.
Objectives: A fully automated insulin-pramlintide-glucagon artificial pancreas that alleviates the burden of carbohydrate counting without degrading glycemic control was iteratively enhanced until convergence through pilot experiments on adults with type 1 diabetes.
Methods: Nine participants (age, 37±13 years; glycated hemoglobin, 7.7±0.
Aim: To assess whether adding empagliflozin to closed-loop automated insulin delivery could reduce the need for carbohydrate counting in type 1 diabetes (T1D) without worsening glucose control.
Materials And Methods: In an open-label, crossover, non-inferiority trial, 30 adult participants with T1D underwent outpatient automated insulin delivery interventions with three random sequences of prandial insulin strategy days: carbohydrate counting, simple meal announcement (no carbohydrate counting) and no meal announcement. During each sequence of prandial insulin strategies, participants were randomly assigned empagliflozin (25 mg/day) or not, and crossed over to the comparator.